{"id":"F2025L00502","name":"Statement of Principles concerning systemic lupus erythematosus (Reasonable Hypothesis) (No. 47 of 2025)","slug":"statement-of-principles-concerning-systemic-lupus-erythematosus-reasonable-hypothesis-no-47-of-2025","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":442820,"registerId":"F2025L00502-fast-fetch-1775957747968","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning systemic lupus erythematosus (Reasonable Hypothesis) (No. 47 of 2025)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n![RMA Australian Government Coat of Arms](image.001.jpeg)\n\n \n\nStatement of Principles\n\nconcerning\n\nSYSTEMIC LUPUS ERYTHEMATOSUS  (Reasonable Hypothesis)\n\n(No. 47 of 2025)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n \n\nDated 15 April 2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nProfessor Terence Campbell AM\n\nChairperson\n\nby and on behalf of\n\nThe Repatriation Medical Authority\n\n \n\n \n\n   \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Repeal\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n \n\n\n\n\n1.                Name\n\n\nThis is the Statement of Principles concerning systemic lupus erythematosus (Reasonable Hypothesis) (No. 47 of 2025).\n\n1.                Commencement\n\n\n              This instrument commences on 19 May 2025.\n\n1.                Authority\n\n\nThis instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n1.                Repeal\n\n\nThe Statement of Principles concerning systemic lupus erythematosus (Reasonable Hypothesis) (No. 21 of 2016) (Federal Register of Legislation No. F2016L00262) made under subsection 196B(2) of the VEA is repealed.\n\n1.                Application\n\n\nThis instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n1.                Definitions\n\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n1.                Kind of injury, disease or death to which this Statement of Principles relates\n  1.           This Statement of Principles is about systemic lupus erythematosus and death from systemic lupus erythematosus.\n\n\nMeaning of systemic lupus erythematosus\n\n1.           For the purposes of this Statement of Principles, systemic lupus erythematosus:\n  1.           means a chronic inflammatory autoimmune disease characterised by the presence of antibodies directed against cell nuclei; and\n  2.           includes:\n    1.             drug induced systemic lupus erythematosus;\n    2.          lupus nephritis; and\n    3.        lupus pneumonitis; and\n  3.           excludes:\n    1.             subacute cutaneous lupus erythematosus;\n    2.          discoid lupus erythematosus; and\n    3.        mixed connective tissue disease.\n\n\nNote: Common clinical manifestations of systemic lupus erythematosus include polyarthritis and arthralgia, photosensitivity, rash, serositis, and renal, haematological and neurological disorders.\n\n1.           While systemic lupus erythematosus attracts ICD‑10‑AM code M32, in applying this Statement of Principles the meaning of systemic lupus erythematosus is that given in subsection (2).\n2.           For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\n\nDeath from systemic lupus erythematosus\n\n1.           For the purposes of this Statement of Principles, systemic lupus erythematosus, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's systemic lupus erythematosus.\n\n\nNote: terminal event is defined in the Schedule 1 – Dictionary.\n\n1.                Basis for determining the factors\n\n\nThe Repatriation Medical Authority is of the view that there is sound medical-scientific evidence that indicates that systemic lupus erythematosus and death from systemic lupus erythematosus can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.\n\nNote: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.\n\n1.                Factors that must exist\n\n\nAt least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting systemic lupus erythematosus or death from systemic lupus erythematosus with the circumstances of a person's relevant service:\n\n1.           being exposed to sunlight or ultraviolet light at a level sufficient to induce erythema (sunburn) at least 24 hours, but not more than 30 days, before clinical worsening of systemic lupus erythematosus skin rash;\n2.           inhaling respirable crystalline silica dust for a cumulative period of at least 1,000 hours before clinical onset or clinical worsening;\n\n\nNote: Examples of when exposure to respirable crystalline silica dust can occur include when material containing crystalline silica is being produced, excavated, drilled, cut or ground, or used in construction, manufacturing, cleaning or blasting.\n\n1.           inhaling respirable crystalline silica dust in an amount greater than 50 micrograms/m3-years of cumulative exposure before clinical onset or clinical worsening;\n\n\nNote 1: Examples of when exposure to respirable crystalline silica dust can occur include when material containing crystalline silica is being produced, excavated, drilled, cut or ground, or used in construction, manufacturing, cleaning or blasting.\n\nNote 2: micrograms/m3-years is defined in the Schedule 1 – Dictionary.\n\n1.           where smoking has not ceased before clinical onset, smoking at least 20 pack-years before clinical onset or clinical worsening;\n\n\nNote: one pack-year is defined in the Schedule 1 – Dictionary.\n\n1.           taking one of the following medications (which cannot be ceased or substituted) at the time of clinical onset or clinical worsening;\n  1.           chlorpromazine;\n  2.           hydralazine;\n  3.           isoniazid;\n  4.           methyldopa;\n  5.           minocycline;\n  6.            procainamide;\n  7.           quinidine;\n  8.           tumour necrosis factor-alpha inhibitors;\n  9.             terbinafine;\n  10.             flutamide;\n  11.           interferon gamma;\n  12.             ethosuximide;\n  13.         oxcarbazepine;\n  14.           carbamazepine;\n  15.           phenytoin.\n2.           taking sulfadiazine or trimethoprim-sulfamethoxazole (which cannot be ceased or substituted) at the time of clinical worsening;\n3.           taking a medication which is associated with:\n  1.           the development of systemic lupus erythematosus including laboratory markers during medication therapy; and\n  2.           the cessation of systemic lupus erythematosus including laboratory markers within 3 months of discontinuing medication therapy; and\n\n\nwhere treatment with the drug continued for at least the 3 days before clinical onset or clinical worsening;\n\n1.           having hormone replacement therapy with an oestrogen for at least the 2 years before clinical onset;\n2.           having a clinically symptomatic bacterial, viral or fungal infection at the time of clinical worsening;\n3.       being pregnant within the 6 weeks before clinical worsening;\n4.       undergoing a thymectomy within the 5 years before clinical onset;\n5.       having posttraumatic stress disorder for at least the 3 months before clinical onset or clinical worsening;\n6.       inability to obtain appropriate clinical management for systemic lupus erythematosus before clinical worsening.\n\n\n1.            Relationship to service\n  1.           The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n  2.           The clinical worsening aspects of factors in section 9  apply only to material contribution to, or aggravation of, systemic lupus erythematosus where the person's systemic lupus erythematosus was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n2.            Factors referring to an injury or disease covered by another Statement of Principles\n\n\nIn this Statement of Principles:\n\n1.           if a factor referred to in section 9 applies in relation to a person; and\n2.           that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;\n\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\n \n\nSchedule 1 - Dictionary  \n\nNote:               See Section 6\n\n1               Definitions\n\nIn this instrument:\n\n                                micrograms/m3-years means micrograms/m3 multiplied by years of exposure.\n\n                               MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n                               one pack-year means the amount of tobacco consumed in smoking 20 cigarettes per day for a period of 1 year, or an equivalent amount of tobacco products.\n\nNote 1: An equivalent amount of tobacco products is 7,300 grams of smoking tobacco by weight, either in cigarettes, pipe tobacco or cigars, or a combination of same. For pipe tobacco, cigars or combinations of multiple tobacco types, 1 gram of tobacco is considered to be equal to one cigarette.\n\nNote 2: Pack-years are calculated by dividing the number of cigarettes smoked per day by 20 and multiplying this number by the number of years the person has smoked. For example, smoking 10 cigarettes per day for 10 years is equal to 5 pack-years, and smoking 40 cigarettes per day for 10 years is equal to 20 pack-years.\n\n                               relevant service means:\n\n(a)          operational service under the VEA;\n\n(b)          peacekeeping service under the VEA;\n\n(c)          hazardous service under the VEA;\n\n(d)          British nuclear test defence service under the VEA;\n\n(e)          warlike service under the MRCA; or\n\n(f)           non-warlike service under the MRCA.\n\nNote: MRCA and VEA are defined in the Schedule 1 - Dictionary.\n\n                               systemic lupus erythematosus—see subsection 7(2).\n\n                               terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a)           pneumonia;\n\n(b)           respiratory failure;\n\n(c)           cardiac arrest;\n\n(d)           circulatory failure; or\n\n(e)           cessation of brain function.\n\n                               VEA means the Veterans' Entitlements Act 1986.\n\n \n\n \n","sortOrder":0}],"analysis":{"flash_summary":{"complexity_score":6,"scope_assessment":{"changed":false,"description":"The instrument repeals the 2016 Statement (section 4) and replaces it with this text that defines SLE, death from SLE, application to VEA/MRCA claims (section 5), and a set of specific factors (section 9) and definitions (Schedule 1). The instrument itself does not state whether these provisions materially expand or narrow coverage compared with the 2016 instrument; determining a substantive change requires direct comparison with the repealed instrument."},"complexity_factors":["Numeric exposure thresholds and time windows (e.g. 1,000 cumulative hours silica, >50 micrograms/m3‑years, 20 pack‑years, pregnancy within 6 weeks, thymectomy within 5 years) creating measurement and evidentiary burden (section 9).","Detailed list of implicated medications and drug‑induced SLE criteria (section 9(5)–(7)) requiring clinical and pharmaceutical records to prove timing and causation.","Interaction between ‘clinical onset’ and ‘clinical worsening’ concepts and the limitation that worsening applies only where SLE existed before/during but did not arise out of service—affects causation analysis (section 10(2)).","Cross‑reference to other Statements of Principles where a factor refers to another injury/disease, adding layered legal interpretation (section 11).","Reliance on the Repatriation Medical Authority’s view of ‘sound medical‑scientific evidence’ and the ‘reasonable hypothesis’ standard—administrative judgement influences outcomes (section 8; section 9 header).","Defined technical measures and units in the Schedule (micrograms/m3‑years, pack‑year equivalence) that require expert quantification and records (Schedule 1).","Application limited to claims under specific statutes (VEA section 120A; MRCA section 338) which focuses impact but requires claim‑level procedural steps (section 5).","Inclusion and exclusion definitions for SLE subtypes and terminal events (section 7 and Schedule 1) that constrain which diagnoses qualify."],"plain_english_summary":"This instrument replaces the prior Statement and sets the medical criteria the Repatriation Medical Authority will use to decide whether systemic lupus erythematosus (SLE) or death from SLE can be reasonably connected to a person’s military \"relevant service.\" \n\nIt lists specific exposures, medications, clinical events and time windows that, if linked to service, raise a \"reasonable hypothesis\" for entitlements under the VEA or MRCA and so affect veterans, serving members and their claim outcomes."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"},"kimi_summary":{"content_quality":"ok","complexity_score":4,"scope_assessment":{"changed":false,"description":"This is a standard replacement Statement of Principles (SOP) under the veterans' compensation framework. It maintains the established scope of determining service-relatedness for a specific disease under the 'reasonable hypothesis' standard. The 2025 version updates medical-scientific evidence but does not expand beyond the original purpose of providing compensation pathways for SLE in the veteran population."},"complexity_factors":["Moderate cross-referencing between the VEA and MRCA compensation schemes","13 distinct causal factors with varying temporal requirements (ranging from 3 days to 5 years before onset/worsening)","Dual triggers — 'clinical onset' vs 'clinical worsening' — with different rules applying to each","Specific quantitative thresholds (1,000 hours silica, 50 micrograms/m3-years, 20 pack-years, 2 years HRT)","Nested definitions requiring lookup in Schedule 1 (micrograms/m3-years, pack-years, terminal event, relevant service)","Conditional logic in section 10(2) restricting 'clinical worsening' claims to pre-existing conditions not arising from service","Inclusion/exclusion criteria for disease subtypes (includes drug-induced lupus and lupus nephritis; excludes discoid and subacute cutaneous forms)","Reference to external classification system (ICD-10-AM Tenth Edition) with specific edition and ISBN citation"],"plain_english_summary":"This instrument sets rules for when Australian veterans and past/current defence personnel (claiming under the VEA or MRCA) can get compensation for systemic lupus erythematosus (SLE) arising from operational, peacekeeping, hazardous or nuclear test service. It applies a \"reasonable hypothesis\" standard: if a veteran shows at least one listed service‑related factor (e.g., silica, heavy smoking, certain drugs, PTSD, UV exposure) linked to service, SLE is presumed service-related for compensation purposes."}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-systemic-lupus-erythematosus-reasonable-hypothesis-no-47-of-2025","history":"/api/acts/statement-of-principles-concerning-systemic-lupus-erythematosus-reasonable-hypothesis-no-47-of-2025/history","analysis":"/api/acts/statement-of-principles-concerning-systemic-lupus-erythematosus-reasonable-hypothesis-no-47-of-2025/analysis","conflicts":"/api/acts/statement-of-principles-concerning-systemic-lupus-erythematosus-reasonable-hypothesis-no-47-of-2025/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-systemic-lupus-erythematosus-reasonable-hypothesis-no-47-of-2025/important-cases","documents":"/api/acts/statement-of-principles-concerning-systemic-lupus-erythematosus-reasonable-hypothesis-no-47-of-2025/documents"}}